Natural Capsules Limited has informed the Exchange about General Updates
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natural Capsules Limited's board approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, revenue from operations rose about 13% to Rs 4,424.29 lakhs (from Rs 3,913.59 lakhs in Q1 FY25), while net profit jumped roughly 73% to Rs 252.30 lakhs (from Rs 145.91 lakhs), giving EPS of Rs 2.44. On a consolidated basis, however, the company swung to a net loss of Rs 558.05 lakhs versus a profit of Rs 60.33 lakhs a year ago, with loss per share of Rs 5.40. The consolidated loss is driven mainly by the newly started API subsidiary Natural Biogenex Private Limited (commenced operations March 31, 2025), where pre-operative expenses, higher depreciation and finance costs pushed the API segment to a Rs 698.55 lakh loss in the quarter. Statutory auditor P. Chandrasekar LLP issued an unmodified limited review conclusion on both sets of results.
Standalone results are healthy with strong profit growth, but the consolidated loss may weigh on the stock in the near term as the new API subsidiary is still in its ramp-up phase. Shareholders should monitor the API segment's revenue ramp-up in coming quarters, as its performance will determine whether the consolidated picture recovers.